Colivelin prolongs survival of an ALS model mouse

Tomohiro Chiba, Marina Yamada, Jumpei Sasabe, Kenzo Terashita, Sadakazu Aiso, Masaaki Matsuoka, Ikuo Nishimoto

Research output: Contribution to journalArticle

32 Citations (Scopus)

Abstract

Amyotrophic lateral sclerosis (ALS) is the most common motor neuron disease for which there is no sufficiently effective therapy. We have reported in our earlier study that intracerebroventricular (i.c.v.) injection of activity-dependent neurotrophic factor (ADNF) improves motor performance of G93A-SOD1 transgenic mice without significant prolongation in survival. Here, we found that i.c.v. injection of a synthetic hybrid peptide named Colivelin composed of ADNF and AGA-(C8R)HNG17, a potent derivative of Humanin that is a bioactive peptide with anti-Alzheimer's disease activity, dose-dependently improved motor performance and prolonged survival of ALS mice. Histological analysis, performed at the age of 120 days, demonstrated increased motoneuronal survival in spinal cords of Colivelin-treated mice as compared with saline- or ADNF-treated mice, indicating that Colivelin is a promising neurotrophic peptide for treatment of ALS.

Original languageEnglish
Pages (from-to)793-798
Number of pages6
JournalBiochemical and Biophysical Research Communications
Volume343
Issue number3
DOIs
Publication statusPublished - 2006 May 12

    Fingerprint

Keywords

  • ADNF
  • ALS
  • Colivelin
  • Humanin
  • Neuroprotection
  • SOD1

ASJC Scopus subject areas

  • Biophysics
  • Biochemistry
  • Molecular Biology
  • Cell Biology

Cite this

Chiba, T., Yamada, M., Sasabe, J., Terashita, K., Aiso, S., Matsuoka, M., & Nishimoto, I. (2006). Colivelin prolongs survival of an ALS model mouse. Biochemical and Biophysical Research Communications, 343(3), 793-798. https://doi.org/10.1016/j.bbrc.2006.02.184